Shorts are not analyzing the numbers right. The non-responders will not lose weight. That was about 1/3 of the trial. There failure to respond does not affect the RESPONDERS at all. Also, forget about the placebo effect for real world results. The FDA was interested in the difference between Belviq and a placebo, but the only number that really matter IS the weight loss by responders.
That is 11% loss in a year. That is not far off from Qsymia but... the trials were designed differently so it may not be apples to apples.
That is why for over a year I have been saying if Belviq helps 6 out of 10 patients who try it the drug should be approved and should be a big success. Now for those 4 that don't respond their doctor can combo Belviq and Phen and if at least half of those respond the you have 8 out of 10 that can successfully lose weight and get healthy. It is a great product and a great company and all the bashers are only looking at one thing to lie, cheat and steal to make a buck.
Longs will made a buck but do so from the success of the drug and its patients.
Pooled data for the extensive non-diabetic clinical trials..... average weight loss across the board for those that took the drug for a year was 8% BW and for the 2/3 of those patients that were responders (greater than 5% BW lost) the average was 11% (B+B pooled data).
1775 total test patients took Belviq as prescribed:
63.9% had AT LEAST 5% BW loss
34.7% got MORE THAN 10% BW loss
top 25% had an average of 35 lbs lost
An all in intent to treat (ITT) of 8% is highly efficacious by itself. Gastro surgery screening at one of our local hospitals requires obese patients to lose 10% BW on their own prior to being short listed for surgery. It is difficult for adults set in their behaviors to lose 10% by diet and exercise alone, regardless of what you weigh. Seeing 1/4 of responders of patients losing 35 lbs is very significant and very rewarding. People will pay for it when they start to see results. Especially if they have tried a failed previously. Keep in mind that this is monotherapy, (adjunct to diet counselling and exercise), and without considering improvements in markers of diabetic control. This product has legs man.
Sentiment: Strong Buy
The problem is all the people who quit for futility before a year . You talk the lucky few. Dr's , the FDA and customers talk about the average person laying out 800 dollars in 12 weeks. Not pretty the numbers. Per the Co less than 40% will be around in 12 weeks. Ouch